These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 22226407

  • 21. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy.
    Akiskal HS, Benazzi F, Perugi G, Rihmer Z.
    J Affect Disord; 2005 Apr; 85(3):245-58. PubMed ID: 15780694
    [Abstract] [Full Text] [Related]

  • 22. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects.
    Levitan RD, Shen JH, Jindal R, Driver HS, Kennedy SH, Shapiro CM.
    J Psychiatry Neurosci; 2000 Sep; 25(4):337-46. PubMed ID: 11022398
    [Abstract] [Full Text] [Related]

  • 23. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
    Gaynor PJ, Gopal M, Zheng W, Martinez JM, Robinson MJ, Marangell LB.
    Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
    [Abstract] [Full Text] [Related]

  • 24. Do estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women.
    Pae CU, Mandelli L, Han C, Ham BJ, Masand PS, Patkar AA, Steffens DC, De Ronchi D, Serretti A.
    Neuro Endocrinol Lett; 2008 Aug; 29(4):500-6. PubMed ID: 18766158
    [Abstract] [Full Text] [Related]

  • 25. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.
    Iovieno N, Tedeschini E, Bentley KH, Evins AE, Papakostas GI.
    J Clin Psychiatry; 2011 Aug; 72(8):1144-51. PubMed ID: 21536001
    [Abstract] [Full Text] [Related]

  • 26. Sponsorship, antidepressant dose, and outcome in major depressive disorder: meta-analysis of randomized controlled trials.
    Sinyor M, Schaffer A, Smart KA, Levitt AJ, Lanctôt KL, Grysman NH.
    J Clin Psychiatry; 2012 Feb; 73(2):e277-87. PubMed ID: 22401489
    [Abstract] [Full Text] [Related]

  • 27. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
    Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA.
    Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
    [Abstract] [Full Text] [Related]

  • 28. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [Abstract] [Full Text] [Related]

  • 29. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
    Mallinckrodt CH, Watkin JG, Liu C, Wohlreich MM, Raskin J.
    BMC Psychiatry; 2005 Jan 04; 5():1. PubMed ID: 15631624
    [Abstract] [Full Text] [Related]

  • 30. Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials.
    Soares CN, Kornstein SG, Thase ME, Jiang Q, Guico-Pabia CJ.
    J Clin Psychiatry; 2009 Oct 04; 70(10):1365-71. PubMed ID: 19906341
    [Abstract] [Full Text] [Related]

  • 31. Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response.
    Kobak KA, Leuchter A, DeBrota D, Engelhardt N, Williams JB, Cook IA, Leon AC, Alpert J.
    J Clin Psychopharmacol; 2010 Apr 04; 30(2):193-7. PubMed ID: 20520295
    [Abstract] [Full Text] [Related]

  • 32. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec 04; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 33. Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects.
    Pae CU, Mandelli L, Kim TS, Han C, Masand PS, Marks DM, Patkar AA, Steffens DC, De Ronchi D, Serretti A.
    Biomed Pharmacother; 2009 Mar 04; 63(3):228-35. PubMed ID: 18502089
    [Abstract] [Full Text] [Related]

  • 34. Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression.
    Zimmerman M, Posternak MA, Chelminski I.
    J Psychiatr Res; 2004 Mar 04; 38(6):577-82. PubMed ID: 15458853
    [Abstract] [Full Text] [Related]

  • 35. Comparison of venlafaxine alone versus venlafaxine plus bright light therapy combination for severe major depressive disorder.
    Güzel Özdemir P, Boysan M, Smolensky MH, Selvi Y, Aydin A, Yilmaz E.
    J Clin Psychiatry; 2015 May 04; 76(5):e645-54. PubMed ID: 26035199
    [Abstract] [Full Text] [Related]

  • 36. Efficacy versus effectiveness: a direct comparison of the outcome of treatment for mild to moderate depression in randomized controlled trials and daily practice.
    van der Lem R, van der Wee NJ, van Veen T, Zitman FG.
    Psychother Psychosom; 2012 May 04; 81(4):226-34. PubMed ID: 22584117
    [Abstract] [Full Text] [Related]

  • 37. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach.
    Tedeschini E, Fava M, Papakostas GI.
    J Clin Psychiatry; 2011 Jan 04; 72(1):98-113. PubMed ID: 21208576
    [Abstract] [Full Text] [Related]

  • 38. Has the symptom severity inclusion requirement narrowed the definition of major depressive disorder in antidepressant efficacy trials?
    Zimmerman M, Walsh E, Chelminski I, Dalrymple K.
    J Affect Disord; 2017 Mar 15; 211():60-64. PubMed ID: 28088058
    [Abstract] [Full Text] [Related]

  • 39. Randomized clinical trials underestimate the efficacy of antidepressants in less severe depression.
    Isacsson G, Adler M.
    Acta Psychiatr Scand; 2012 Jun 15; 125(6):453-9. PubMed ID: 22176585
    [Abstract] [Full Text] [Related]

  • 40. Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depression.
    Dreimüller N, Schlicht KF, Wagner S, Peetz D, Borysenko L, Hiemke C, Lieb K, Tadić A.
    Neuropharmacology; 2012 Jan 15; 62(1):264-9. PubMed ID: 21803060
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.